TSHA - Taysha Gene Therapies Inc
Taysha Gene Therapies Inc Logo

TSHA - Taysha Gene Therapies Inc

https://www.tayshagtx.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.

52W High
$3.40
52W Low
$1.05
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.96
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.61
EV/Revenue (<3 favorable)
81.92
P/S (TTM) (<3 favorable)
113.19
P/B (<3 favorable)
3.69
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
11.15%
Institutions (25–75% balanced)
94.71%
Shares Outstanding
272,795,000
Float
173,268,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
8,098,000
Gross Profit (TTM)
8,098,000
EPS (TTM)
-0.34
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-13.47%
ROE (TTM) (>15% strong)
-0.52%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.79
Momentum
Bearish momentum
Value
0.1376
Previous
0.1584
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025